303 related articles for article (PubMed ID: 28455944)
1. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
2. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study.
Burnett AL; Walker DR; Feng Q; Johnston KM; Lozano-Ortega G; Nimke D; Hairston JC
Neurourol Urodyn; 2020 Jun; 39(5):1378-1386. PubMed ID: 32383533
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
Mullen GR; Kaplan SA
Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
[TBL] [Abstract][Full Text] [Related]
4. The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms.
Kosilov K; Kuzina I; Kuznetsov V; Kosilova L; Ivanovskaya M; Kosilova E
Curr Aging Sci; 2020; 13(1):72-80. PubMed ID: 31560296
[TBL] [Abstract][Full Text] [Related]
5. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
6. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.
Lee D; Koo KC; Yoo JW; Lee KS
Low Urin Tract Symptoms; 2022 Jan; 14(1):35-40. PubMed ID: 34323012
[TBL] [Abstract][Full Text] [Related]
7. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
8. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
9. Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.
Welliver C; Feinstein L; Ward JB; Fwu CW; Kirkali Z; Bavendam T; Matlaga BR; McVary KT;
J Urol; 2020 Jan; 203(1):171-178. PubMed ID: 31430232
[TBL] [Abstract][Full Text] [Related]
10. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
11. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.
Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S
Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028
[TBL] [Abstract][Full Text] [Related]
12. Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
Tsujimura A; Takao T; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Kiuchi H; Hirai T; Tsujimoto Y; Miura H; Kanno N; Higashino M; Nakamura Y; Nishimura K; Nonomura N
Urology; 2011 Nov; 78(5):1058-62. PubMed ID: 21908025
[TBL] [Abstract][Full Text] [Related]
13. [Urinary prostaglandins E2 correlates to overactive bladder symptoms in patients with benign prostatic hyperplasia].
Zhang YJ; Bai Q
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):244-8. PubMed ID: 24738462
[TBL] [Abstract][Full Text] [Related]
14. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Lua LL; Pathak P; Dandolu V
Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
[TBL] [Abstract][Full Text] [Related]
15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
16. [Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice].
Matsukawa Y; Funahashi Y; Gotoh M
Nihon Yakurigaku Zasshi; 2019; 154(5):265-269. PubMed ID: 31735756
[TBL] [Abstract][Full Text] [Related]
17. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
